The business uses TFF technology. Thanks, Glenn good been our creating on Film partners of Thin has potential group focused and of in characteristics beneficial afternoon, and potential an at awareness the educating Freezing development everyone.
with planting our making We the starting bear our have business with have been fruit. now efforts and technology development we delivery to Well, been partners. are tremendous potential strides seeds
on areas. Our business three focus initiatives and development goals key
Growing First, with and large from these developing value internal our technology, developing inflection the these pipeline, of characteristics we enabling pipeline. that points products products commercial and defined innovative to are focused partnering benefit products on our new of with our organizations. goal the
we our by continue grow. successfully interest pipeline level As progress to products development, of to through potential continues the partners
ongoing. and multiple discussions We fluid discussions and have are engaged in with companies partnering these
of pharma area better The cold-chain removing and products improved these collaborations name their new new and is and and/or costs expense the to products taking these and in small, of our with either a route few. partners, both technology a absorption making administration, proprietary second through handling formulating products, just focus of large
elements. two explore the to a prior the Freezing previously are updates, agreement of work our lung which undisclosed of worldwide feasibility with company perform into As for both NCEs an on of to formulate, Thin directly is leading on of delivery their technology work new using optimization to ongoing. testing and entities disclosed compounds chemical compounds, still This these proprietary Film or treatment for respiratory entered we biopharmaceutical
are liquid reconstitution. formulate dry using explore formulation we technology for collaborating vaccine large partner’s antiviral our a disclosed, previously as Phase into a to Also to X pharma with company platform the powder multinational
dry animal has We is formulation powder confirmed the in specifications has have testing, the vaccine their the performed as internal partner testing liquid that and development. TFF the currently completed which same
and Ongoing ongoing. testing additional is formulation, optimization
to formulating for partners lungs. on powder siRNA, vaccines bacteria, work We plasmid mRNA, proprietary and delivery with directly pharma numerous their TFF continue to bacteriophage, work, the the dry into inhalation feasibility DNA,
We that partners the bear work in will future. this with formulation are feasibility our very fruit near hopeful and
collaboration include turn feasibility would into technology, the payment and include arrangements license full upfront the to respective development royalties successful be development, to with to milestones granting a blown work, partners. our of TFF in enter These would then each our and agreement partner, Pharma. Upon goal an a would and
is institution referred with biological research the Diseases, as are research to a focus into of on Army collaborating cooperative Army’s countermeasures defensive third Infectious Institute XX, for for as against and April working we agencies that Alphaviruses under Filoviruses. entered premier announced novel with agreement antigens to United publicly area USAMRIID We Medical and Now, refer CRADA with facility foundations. and States This we and treating government Back a the into development warfare. USAMRIID. U.S. is Research
terms the the CRADA, over the different formulate Thin of technology period a to Freezing Under to investigate collaborate countermeasures. Film three-year USAMRIID Pharma TFF will the and using
a being The Venezuelan, Alphaviruses, Western, first such antibody monoclonal encephalitis equine as Eastern viruses. against and
The against pulmonary the in route as virus a dry Filoviruses, Ebola the a Marburg. USAMRIID powder to compared the stomatitis immune by model, by will rodent responses vaccine such the routes evaluate TFF second induced vesicular given being and of formulations traditional administration. as
a and honored very scientific to be Dr. research working developed vaccines his prestigious group of is following Dr. collaboration is we Immunology. the Ebola on and on Center CVI vaccine. April symptom that we the know, are for freezing and team process. Vaccines TFF with with researchers proud at announced universal USAMRIID. or may for Georgia’s the that vaccine Dye, We of The a Also the and working a efficacy Immunology Center the Dye of with Vaccines John and you into as team immunogenicity to of X, publicly member influenza influenza entered evaluate UGA’s University universal
of the vaccine. the collaborate to PFF-formulated the University and TFF collaboration, Under investigate influenza will CVI universal terms recombinant of Georgia’s
Freezing honored collaborating rodent model. TFF such collaborating are Ted group of adjuvant lasting of TFF responses. the potentially again, a viruses with using a formulated ought elicit with is broadly will proteins researchers of prestigious CVI group without these CVI once world preclinical The of protection leaders and vaccine be to in this the University influenza Pharma wider TFF development, prestigious such a variety challenge evaluate technology. part longer of the and then They Georgia’s provide a of collaboration, As at researchers, Film in ability formulate Pharma our researchers. Georgia’s Ross compounds against immune Thin different be Dr. will University to reactive and to with, of
for on on proposal the a protective announced partner company the February Agency, its program. through personalized previously earnings we our agency broad submitted along with the DARPA last biosystem as Advanced Research Also, XX, process call the announcement Projects Defense to
granted XX after We days notified expect XX date to submission. is the if the be award an to award days of of within
outcome designated time months. to in that the are we a will we currently positive be this are award hopeful period in able We this and report of upcoming
to continue actively key these we closing, in areas. and each partnerships pursue In three collaborations of
growing focus the are Our programs, our internal government partners, of our company. for development agencies. pharma and These areas
to our critical University business these created While the collaboration, This this the think it efforts Austin, I are of continue is by of new University research the at expand I of Texas Film Thin tireless a by Austin. our of supported efforts William collaboration partners reinforce developed opportunity, support areas Texas Williams all of Dr. it’s the the strongest had Dr. at of was and at at partnership Bill Freezing delivery. and and technology to and team, support the his of with we innovative and applications technology, development
scratched As often I many the Film the Freezing applications you’ve say, of Thin only surface technology. of the
With of Thank your it you hand for now much over said, Glenn. that all time I will very today. to back
